about
Second-line chemotherapy with irinotecan and vinorelbine in stage IIIB and IV non-small-cell lung cancer: a phase II study.Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer.Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancer.A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.Rectal cancer treatment: improving the picture.Predictive factors for radiation-induced pulmonary toxicity after three-dimensional conformal chemoradiation in locally advanced non-small-cell lung cancer.Pneumomediastinum as a complication of SABR for lung metastasesDendritic cell vaccination in glioblastoma after fluorescence-guided resectionSalvage surgery and radiotherapy including intraoperative electron radiotherapy in isolated locally recurrent tumors: Predictors of outcome.Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients.Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium.Influence of different treatment techniques and clinical factors over the intrafraction variation on lung stereotactic body radiotherapy.Multicatheter breast implant during breast conservative surgery: Novel approach to deliver accelerated partial breast irradiation.Pilot study of concurrent cisplatin, 5-fluorouracil, and external beam radiotherapy prior to radical surgery +/- intraoperative electron beam radiotherapy in locally advanced cervical cancer.Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer.cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted.Phase I-II trial of concurrent capecitabine and oxaliplatin with preoperative intensity-modulated radiotherapy in patients with locally advanced rectal cancer.Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors.Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.Rescuing Spanish Radiation Therapy: The Role of Leadership and Opportunity.An independent algorithm to check the monitor units calculation in radiosurgery.A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer.Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.Biological and clinical significance of the intratumour heterogeneity of PTEN protein expression and the corresponding molecular abnormalities of the PTEN gene in glioblastomas.Voxel-based analysis of dual-time-point 18F-FDG PET images for brain tumor identification and delineation.Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumabIntraoperative radiotherapy in recurrent gynecological cancerIntraoperative radiotherapy in locally advanced recurrent colorectal cancerCisplatin, mitomycin, and vindesine followed by intraoperative and postoperative radiotherapy for stage III non-small cell lung cancer: final results of a phase II studyLong-term normal tissue effects of intraoperative electron radiation therapy (IOERT): late sequelae, tumor recurrence, and second malignanciesPatterns of failure and long-term results in high-risk resected gastric cancer treated with postoperative radiotherapy with or without intraoperative electron boostRadiation therapy after high-dose chemotherapy with peripheral blood stem cell support for high-risk breast cancerInduction platinum-based chemotherapy followed by radical hyperfractionated radiotherapy with concurrent chemotherapy in the treatment of locally advanced non-small-cell carcinoma of the lungAnalysis of early postoperative morbidity among patients with rectal cancer treated with and without neoadjuvant chemoradiotherapyFour-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trialPhase I-II trial of perioperative high-dose-rate brachytherapy in oral cavity and oropharyngeal cancerComparison of limited-volume perioperative high-dose-rate brachytherapy and wide-field external irradiation in resected head and neck cancerRole of surgery in a multidisciplinary approach to superior sulcus tumors (SST): morbidity and prognostic factors for long-term success after resectionPatterns of response after preoperative treatment in gastric cancer
P50
Q33344889-E3FCD814-2A0C-4F4B-B211-133FA654A0F4Q33345489-B333F278-92E5-4EE0-AE17-6601069CE736Q33361052-2796FBB1-5575-4A00-8F25-FE76BACE98B9Q33668084-C9C54290-5F4E-442C-AD19-7DD6B1DF760FQ34143185-D041F5F7-D167-47E1-8959-6F2D52CC6C69Q34382761-50829C9D-57E8-482A-9924-8782A2415AB1Q34699304-D0F33909-7F85-4480-AE1A-AE2D5C7D4055Q35036765-F4D091A2-DFF7-4991-B818-ACDE47EE1EF4Q36507978-6B4481C5-DE08-4FEF-96B6-BF1C7D8B5018Q38558697-DF2B8A8A-0695-45EC-A9F1-0574626E1DA6Q38560967-7CEB70FB-B0CA-4B38-B3E7-EC27500E2309Q38722331-FEDD4705-BFC2-4544-97B3-94E8DA8DC279Q40116176-3F0C5A28-68C3-4296-BB68-32447D61A346Q40693690-9B20D3E7-5DA0-488C-8922-B14AC733AEADQ44140922-19ADFA97-04BC-42F8-8EE8-86CEBB005AA3Q44308888-FCCD6CC8-B5E4-4207-8F75-C5FCD956DD6AQ46803172-EE9075A8-6BE6-49C7-A11A-74075D5E5B01Q46828830-A7484E77-0BD6-47CD-86B4-0008B303D851Q46939586-63537CD9-1FDF-463C-932C-FF93E97F1DD5Q47846644-D26DB3D6-712C-4A52-8A83-E46EAEC25E3DQ49896505-D5B5579A-FC89-4450-B9FA-2995137D31A3Q51892387-B8613309-7513-4B5C-8EE0-D2D9FB277003Q53179508-DF91D194-3C71-4546-AE8F-D489F4C6944BQ53191177-CB559F6C-6CCF-47CE-AD9B-8DFC30A96AC6Q55461275-5A3D12FF-B55D-4E55-A736-A563FC15CC70Q55463088-8B6C23B7-4B45-48ED-B2A8-903651F18CC8Q63865746-68A1347B-45F9-4B67-902B-9B6C40D40AC0Q72627463-FC360FA0-AF67-4472-8C1D-8998ED79C8B7Q72865204-E00ABD19-D80D-4AEB-9A9C-DAD0CA60DC77Q73376773-D941D983-017C-4F88-A062-118A125D3980Q73428734-1D0A7C7D-C709-4861-AF08-ED9F2377417DQ73682704-0BBD8030-5B48-428E-B32A-A5C384BE3A2AQ74551336-9AFA87D7-9B27-4DB7-82F5-F86D2B05D25EQ77311190-3AA9F3F3-AFBC-4AC1-A68F-23073A97AB81Q79864229-8A79AFDE-588E-4C2E-A243-1583BFB41B44Q82485474-8D1C2A57-3F0B-4DA4-85CD-BBB83E43A00EQ82762681-3376B010-9F26-4685-B0F9-9362D8A7C511Q83300510-26D5035A-0C51-4998-A53B-233C27496581Q84467822-12B249A6-E5B4-45A8-8109-D58B283521A4Q84591595-B6841033-0BFE-48C2-B28E-03162E209893
P50
description
forsker
@nb
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
J. Aristu
@ast
J. Aristu
@nl
Javier Aristu
@en
Javier Aristu
@es
Javier Aristu
@nb
type
label
J. Aristu
@ast
J. Aristu
@nl
Javier Aristu
@en
Javier Aristu
@es
Javier Aristu
@nb
altLabel
J. Aristu
@en
prefLabel
J. Aristu
@ast
J. Aristu
@nl
Javier Aristu
@en
Javier Aristu
@es
Javier Aristu
@nb
P106
P31
P496
0000-0002-0382-2363